Evidence map›Paper›PMID 37298099›Full record

ArticleInternational journal of molecular sciences2023

Pevonedistat Inhibits SOX2 Expression and Sphere Formation but Also Drives the Induction of Terminal Differentiation Markers and Apoptosis within Arsenite-Transformed Urothelial Cells.

Aaron A Mehus, Madison Jones, Mason Trahan, Kaija Kinnunen, Kaitlyn Berwald, Becker Lindner, Sarmad Al-Marsoummi, Xu Dong Zhou, Scott H Garrett, Donald A Sens and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The transcription factor sex-determining region Y-box 2 (SOX2) in bladder cancer.American journal of clinical and experimental urology · 2024
    Article
  7. Article
  8. Editorial: Special Issue "Stem Cell Biology and Cancer".International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Aaron A MehusDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Madison JonesDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Mason TrahanDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Kaija KinnunenDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Kaitlyn BerwaldDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Becker LindnerDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Sarmad Al-MarsoummiDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Xu Dong ZhouDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Scott H GarrettDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Donald A SensDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Mary Ann SensDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
Seema SomjiDepartment of Pathology, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND 58202, USA.
University of North Dakota · US

Funding

Research CoresP20GM103442 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI Donald A. Sens · 2012 to 2026
$53.0M
Supplement for Google cloud build-outR24GM137786 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Alan Tackett · 2020 to 2026
$15.4M
NIGMS NIH HHS P20 GM103442NIGMS NIH HHS R24 GM137786
6 · The paper itself

Abstract

Urothelial cancer (UC) is a common malignancy and its development is associated with arsenic exposure. Around 25% of diagnosed UC cases are muscle invasive (MIUC) and are frequently associated with squamous differentiation. These patients commonly develop cisplatin (CIS) resistance and have poor prognosis. SOX2 expression is correlated to reduced overall and disease-free survival in UC. SOX2 drives malignant stemness and proliferation in UC cells and is associated with development of CIS resistance. Using quantitative proteomics, we identified that SOX2 was overexpressed in three arsenite (As

Indexed as

ArsenitesCarcinoma, Transitional CellUrinary Bladder NeoplasmsAntigens, DifferentiationApoptosisCell Line, TumorCell ProliferationCisplatinCyclopentanesHumansPyrimidinesSOXB1 Transcription FactorsAntigens, DifferentiationarseniteArsenitesCisplatinCyclopentanespevonedistatPyrimidinesSOX2 protein, humanSOXB1 Transcription Factorsarsenitebasalstem cellsterminal differentiationurothelial carcinoma

Identifiers

PMID37298099
PMCPMC10252886
OpenAlexW4378086687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.